2-(n-myristoylamino)-1-phenyl-1-propanol profile

2-(N-myristoylamino)-1-phenyl-1-propanol: ceramidase inhibitor; RN given for ((R*,S*)-(+-))-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	124735
CHEMBL ID	429926
CHEBI ID	93338
SCHEMBL ID	611869
MeSH ID	M0261565

Synonym
CBIOL_001751
BRD-K76274772-001-02-7
BIO1_000037
BIO1_000526
BIO1_001015
BIO2_000128
BIO2_000608
BSPBIO_001408
NCGC00161371-01
NCGC00161371-02
d-erythro-mapp
KBIO2_005264
KBIO3_000255
KBIO2_002696
KBIOGR_000128
KBIOSS_000128
KBIO2_000128
KBIO3_000256
IDI1_033878
NCGC00161371-03
HMS1989G10
60847-25-8
BML3-E01
mapp, d-erythro
HMS1361G10
HMS1791G10
CHEMBL429926 ,
n-[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]tetradecanamide
143492-38-0
(1s,2r-d-erythro-2-n-myristoylamino)-1-phenyl-1-propanol
bdbm50392473
2-(n-myristoylamino)-1-phenyl-1-propanol
(r,s)-(+-)-n-(2-hydroxy-1-methyl-2-phenylethyl)tetradecanamide
tetradecanamide, n-(2-hydroxy-1-methyl-2-phenylethyl)-, (r,s)-(+-)-
SCHEMBL611869
d-erythro-2-tetradecanoylamino-1-phenyl-1-propanol
143492-39-1
HMS3648G09
HMS3402G10
gtpl8817
d-e-mapp
CHEBI:93338
J-007821
n-(1-hydroxy-1-phenylpropan-2-yl)tetradecanimidic acid
DTXSID00931906
Q27077017
sr-01000946211
SR-01000946211-1
MS-25732
n-((1s,2r)-1-hydroxy-1-phenylpropan-2-yl)tetradecanamide
CS-0138591
HY-137422
AKOS040755605

Excerpt	Relevance	Reference
" Time- and dose-response studies on the effects of these compounds on Cer species and Sph levels, combined with structure-activity relationship (SAR) data, revealed 4 distinct classes of analogs which were predominantly defined by modifications of the N-acyl-hydrophobic interfaces: N-acyl-analogs (class A), urea-analogs (class B), N-alkyl-analogs (class C), and omega-cationic-N-acyl analogs (class D)."	( Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bai, A; Bielawska, A; Bielawski, J; Elojeimy, S; Hannun, YA; Liu, X; Mayroo, N; Norris, JS; Pierce, J; Rembiesa, B; Szulc, ZM, 2008)	0.35

Class	Description
alkylbenzene	A monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	44.6684	0.0112	12.4002	100.0000	AID1030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Acid ceramidase	Homo sapiens (human)	IC50 (µMol)	333.6667	0.0207	0.4925	1.0000	AID1707269; AID1707270; AID691433
Alkaline ceramidase 2	Homo sapiens (human)	IC50 (µMol)	1.0000	1.0000	1.0000	1.0000	AID734964
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
fatty acid metabolic process	Acid ceramidase	Homo sapiens (human)
keratinocyte differentiation	Acid ceramidase	Homo sapiens (human)
sphingosine biosynthetic process	Acid ceramidase	Homo sapiens (human)
ceramide biosynthetic process	Acid ceramidase	Homo sapiens (human)
ceramide catabolic process	Acid ceramidase	Homo sapiens (human)
regulation of steroid biosynthetic process	Acid ceramidase	Homo sapiens (human)
regulation of programmed necrotic cell death	Acid ceramidase	Homo sapiens (human)
cellular response to tumor necrosis factor	Acid ceramidase	Homo sapiens (human)
negative regulation of cell-matrix adhesion	Alkaline ceramidase 2	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Alkaline ceramidase 2	Homo sapiens (human)
DNA damage response	Alkaline ceramidase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Alkaline ceramidase 2	Homo sapiens (human)
regulation of autophagy	Alkaline ceramidase 2	Homo sapiens (human)
sphingolipid catabolic process	Alkaline ceramidase 2	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Alkaline ceramidase 2	Homo sapiens (human)
response to retinoic acid	Alkaline ceramidase 2	Homo sapiens (human)
negative regulation of cell adhesion mediated by integrin	Alkaline ceramidase 2	Homo sapiens (human)
regulation of apoptotic process	Alkaline ceramidase 2	Homo sapiens (human)
sphingosine biosynthetic process	Alkaline ceramidase 2	Homo sapiens (human)
ceramide catabolic process	Alkaline ceramidase 2	Homo sapiens (human)
regulation of protein glycosylation	Alkaline ceramidase 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Alkaline ceramidase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Acid ceramidase	Homo sapiens (human)
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides	Acid ceramidase	Homo sapiens (human)
N-acylsphingosine amidohydrolase activity	Acid ceramidase	Homo sapiens (human)
fatty acid amide hydrolase activity	Acid ceramidase	Homo sapiens (human)
ceramidase activity	Acid ceramidase	Homo sapiens (human)
N-acylsphingosine amidohydrolase activity	Alkaline ceramidase 2	Homo sapiens (human)
metal ion binding	Alkaline ceramidase 2	Homo sapiens (human)
dihydroceramidase activity	Alkaline ceramidase 2	Homo sapiens (human)
ceramidase activity	Alkaline ceramidase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
early endosome	Acid ceramidase	Homo sapiens (human)
endoplasmic reticulum	Acid ceramidase	Homo sapiens (human)
extracellular region	Acid ceramidase	Homo sapiens (human)
extracellular space	Acid ceramidase	Homo sapiens (human)
nucleus	Acid ceramidase	Homo sapiens (human)
lysosome	Acid ceramidase	Homo sapiens (human)
lysosomal lumen	Acid ceramidase	Homo sapiens (human)
extracellular exosome	Acid ceramidase	Homo sapiens (human)
tertiary granule lumen	Acid ceramidase	Homo sapiens (human)
ficolin-1-rich granule lumen	Acid ceramidase	Homo sapiens (human)
Golgi membrane	Alkaline ceramidase 2	Homo sapiens (human)
Golgi apparatus	Alkaline ceramidase 2	Homo sapiens (human)
Golgi membrane	Alkaline ceramidase 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay ID	Title	Year	Journal	Article
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1707269	Inhibition of acid ceramidase in human HL-60 cell lysates	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors.
AID320186	Decrease in endogenous sphingosine level in human MCF7 cells upto 50 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID1707270	Inhibition of acid ceramidase in human HaCaT cell lysates	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors.
AID320173	Increase in endogenous ceramide level in human MCF7 cells at >25 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID691433	Inhibition of aCDase expressed in human HL60 cell extract	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Novel amide- and sulfonamide-based aromatic ethanolamines: effects of various substituents on the inhibition of acid and neutral ceramidases.
AID320185	Increase in endogenous C24:1-ceramide level in human MCF7 cells upto 5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID691427	Inhibition of recombinant human aCDase expressed in Sf9 cells using fluorescently-labeled acyl-NBD-C12-ceramide as substrate at 80 uM after 8 hrs by fluorescence assay	2012	Bioorganic & medicinal chemistry, Oct-15, Volume: 20, Issue:20	Novel amide- and sulfonamide-based aromatic ethanolamines: effects of various substituents on the inhibition of acid and neutral ceramidases.
AID320259	Increase in endogenous C24-ceramide level in human MCF7 cells at 50 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320174	Decrease in endogenous sphingosine level in human MCF7 cells at >2.5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320188	Decrease in endogenous C24-ceramide level in human MCF7 cells at 10 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID734977	Inhibition of human recombinant neutral ceramidase using Acyl-NBD-C12-cer as substrate at 80 uM after 2 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues.
AID734964	Inhibition of alkaline ceramidase 2 in human HL-60 cells using 3H]C16-ceramide as substrate after 1 hr by liquid scintillation counting analysis	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues.
AID320183	Decrease in endogenous C24-ceramide level in human MCF7 cells upto 5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320184	Decrease in endogenous sphingosine level in human MCF7 cells upto 5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID734976	Inhibition of human recombinant acid ceramidase using Acyl-NBD-C12-cer as substrate at 80 uM after 8 hrs by fluorescence assay	2013	Bioorganic & medicinal chemistry, Feb-15, Volume: 21, Issue:4	Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues.
AID320182	Decrease in endogenous C16-ceramide level in human MCF7 cells upto 5 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320113	Antiproliferative activity against human MCF7 cells after 48 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents.
AID320189	Decrease in endogenous C24:1-ceramide level in human MCF7 cells at 10 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
AID320187	Decrease in endogenous C16-ceramide level in human MCF7 cells at 10 uM after 24 hrs	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (9.09)	18.2507
2000's	11 (50.00)	29.6817
2010's	6 (27.27)	24.3611
2020's	3 (13.64)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	23 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carmofur [no description available]	2.25	1	organohalogen compound; pyrimidines
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol: a sphingolipid analog; inhibits the enzyme activity in infected erythrocytes. N-[1-hydroxy-3-(morpholin-4-yl)-1-phenylpropan-2-yl]hexadecanamide : A fatty amide resulting from the formal condensation of palmitic acid with the primary amino group of 2-amino-3-(morpholin-4-yl)-1-phenylpropan-1-ol.	2.43	2	benzyl alcohols; fatty amide; morpholines; secondary alcohol; tertiary amino compound
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.01	1	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	2.02	1	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	2	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
1-deoxynojirimycin 1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.	2.02	1	2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid	anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite
miglustat miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.	2.02	1	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
1-phenyl-2-decanoylamino-3-morpholino-1-propanol RV 538: noninactivating inhibitor of ceramide-UDPG glucosyltransferase; RN given for unspecified HCl; structure given in first source	2.01	1
sr 33557 fantofarone: structure given in first source	2.03	1
n-acetylneuraminic acid N-Acetylneuraminic Acid: An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518). N-acetylneuraminic acid : An N-acylneuraminic acid where the N-acyl group is specified as acetyl.	2.02	1	N-acetylneuraminic acids	antioxidant; bacterial metabolite; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; human metabolite; mouse metabolite
fludarabine [no description available]	2	1	purine nucleoside
fumonisin b1 fumonisin B1: isolated from Fusarium moniliforme MRC 826; structure given in first source; has cancer-promoting activity; inhibits ceramide synthase. fumonisin B1 : A diester that results from the condensation of the 1-carboxy groups of two molecules of propane-1,2,3-tricarboxylic acid with hydroxy groups at positions 14 and 15 of (2S,3S,5R,10R,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,5,10,14,15-pentol.	2.02	1	diester; fumonisin; primary amino compound; triol	carcinogenic agent; metabolite
fumonisin b2 fumonisin B2: produced by Fusarium moniliforme MRC 826; structure given in first source; has cancer-promoting ability. fumonisin B2 : A fumonisin that is (2S,3S,12S,14S,15R,16R)-2-amino-12,16-dimethylicosane-3,14,15-triol in which the hydroxy groups at positions 14 and 15 have each been esterified by condensation with the 1-carboxy group of 3-carboxyglutaric acid (giving a 3-carboxyglutarate ester group with R configuration in each case).	2.03	1	diester; diol; fumonisin; primary amino compound	Aspergillus metabolite; carcinogenic agent
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	2.92	4	sphing-4-enine	human metabolite; mouse metabolite
n,n-dimethylsphingenine N,N-dimethylsphingosine: a sphingosine kinase inhibitor. N,N-dimethylsphingosine : A sphingoid that is sphingosine in which the two amino hydrogens are replaced by methyl groups.	2.02	1	aminodiol; sphingoid; tertiary amino compound	EC 2.7.1.91 (sphingosine kinase) inhibitor; metabolite
n-oleoylethanolamine N-oleoylethanolamine: ceramidase inhibitor. oleoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.	2.53	2	endocannabinoid; N-(long-chain-acyl)ethanolamine; N-acylethanolamine 18:1	EC 3.5.1.23 (ceramidase) inhibitor; geroprotector; PPARalpha agonist
sphingosine 1-phosphate sphingosine 1-phosphate: RN given refers to (R-(R,S-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1	2.01	1	sphingoid 1-phosphate	mouse metabolite; signalling molecule; sphingosine-1-phosphate receptor agonist; T-cell proliferation inhibitor; vasodilator agent
n-palmitoylsphingosine N-palmitoylsphingosine: structure given in first source; RN given refers to (R,S-(E))-isomer. N-hexadecanoylsphingosine : A N-acylsphingosine in which the ceramide N-acyl group is specified as hexadecanoyl (palmitoyl).	2.03	1	Cer(d34:1); N-acylsphingosine; N-palmitoyl-sphingoid base	human blood serum metabolite; Mycoplasma genitalium metabolite
n-acetylsphingosine N-acetylsphingosine: inhibits phospholipase D. N-acetylsphingosine : A N-acylsphingosine that has an acetamido group at position 2.	2.7	3	N-acylsphingosine
n-caproylsphingosine N-(hexanoyl)sphing-4-enine : An N-acylsphingosine consisting of sphing-4-enine bearing a hexanoyl group on nitrogen.	2.42	2	N-acylsphingosine
thermozymocidin thermozymocidin: a serine palmitoyltransferase inhibitor; FTY720 is an analog	2.02	1	alpha-amino fatty acid; hydroxy monocarboxylic acid; non-proteinogenic alpha-amino acid; sphingoid	antifungal agent; antimicrobial agent; antineoplastic agent; apoptosis inducer; EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor; fungal metabolite; immunosuppressive agent
n-hexanoyldihydrosphingosine N-hexanoyldihydroceramide : A dihydroceramide in which the ceramide N-acyl group is specified as hexanoyl.	2.02	1	N-acylsphinganine
sphingosine kinase [no description available]	2.02	1
glycolipids [no description available]	2.45	2

Condition	Relationship Strength	Studies
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Carcinoma, Non-Small Cell Lung [description not available]	2.07	1
Cancer of Lung [description not available]	2.07	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.07	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.07	1
Carcinoma, Epidermoid [description not available]	2.02	1
Cancer of Head [description not available]	2.02	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.02	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.02	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	2	1
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	2	1
Cancer of Colon [description not available]	2	1
Experimental Hepatoma [description not available]	2	1
Colonic Neoplasms Tumors or cancer of the COLON.	2	1
Malignant Melanoma [description not available]	2.01	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.01	1

2-(n-myristoylamino)-1-phenyl-1-propanol

Description

Cross-References

Synonyms (53)

Research Excerpts

Dosage Studied

Drug Classes (1)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (20)

Molecular Functions (7)

Ceullar Components (12)

Bioassays (23)

Research

Studies (22)

Market Indicators

Research Demand Index: 11.95

Study Types

2-(n-myristoylamino)-1-phenyl-1-propanol

Description

Cross-References

Synonyms (53)

Research Excerpts

Dosage Studied

Drug Classes (1)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (20)

Molecular Functions (7)

Ceullar Components (12)

Bioassays (23)

Research

Studies (22)

Market Indicators

Research Demand Index: 11.95

Study Types

Related Drugs (24)

Related Conditions (20)